- Home
- APLS
as 05-17-2024 4:00pm EST
$.
-
$.
-.%
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 5.0B | IPO Year: | 2017 |
| Target Price: | $74.75 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.83 - $94.75 | Next Earning Date: | 05-07-2024 |
| Revenue: | $524,070,000 | Revenue Growth: | 394.93% |
| Revenue Growth (this year): | 104.94% | Revenue Growth (next year): | 48.38% |
Share on Social Networks:
Stock Insider Trading Activity of Apellis Pharmaceuticals Inc. (APLS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Deschatelets Pascal | APLS | Chief Scientific Officer | May 8 '24 | Sell | $44.03 | 100 | $4,402.50 | 1,115,983 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | May 8 '24 | Sell | $42.85 | 22,472 | $962,902.73 | 1,116,083 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | May 8 '24 | Sell | $42.15 | 56,335 | $2,374,542.78 | 1,138,555 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Apr 8 '24 | Sell | $54.12 | 64,379 | $3,483,966.15 | 1,120,711 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Apr 8 '24 | Sell | $54.92 | 4,728 | $259,639.07 | 1,115,983 | SEC Form 4 |
| DeLong Mark Jeffrey | APLS | Chief Business & Strat Officer | Mar 18 '24 | Sell | $56.90 | 9,913 | $564,049.70 | 54,693 | SEC Form 4 |
| Chopas James George | APLS | VP/Chief Accounting Officer | Mar 15 '24 | Sell | $56.46 | 184 | $10,388.82 | 38,883 | SEC Form 4 |
| Nicholson Nur | APLS | Chief Technical Officer | Mar 13 '24 | Sell | $57.31 | 7,768 | $445,160.78 | 59,739 | SEC Form 4 |
| Nicholson Nur | APLS | Chief Technical Officer | Mar 13 '24 | Sell | $58.13 | 3,452 | $200,676.84 | 56,287 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Mar 8 '24 | Sell | $61.88 | 42,750 | $2,645,173.35 | 1,142,340 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Mar 8 '24 | Sell | $62.69 | 26,257 | $1,646,040.83 | 1,116,083 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Mar 8 '24 | Sell | $63.35 | 100 | $6,335.00 | 1,115,983 | SEC Form 4 |
| Sullivan Timothy Eugene | APLS | Chief Financial Officer | Mar 1 '24 | Sell | $62.86 | 4,000 | $251,440.00 | 95,338 | SEC Form 4 |
| Sullivan Timothy Eugene | APLS | Chief Financial Officer | Mar 1 '24 | Sell | $63.95 | 2,000 | $127,900.00 | 93,338 | SEC Form 4 |
| DeLong Mark Jeffrey | APLS | Chief Business & Strat Officer | Feb 12 '24 | Sell | $67.77 | 597 | $40,456.84 | 64,606 | SEC Form 4 |
| Francois Cedric | APLS | Chief Executive Officer | Feb 12 '24 | Sell | $67.77 | 3,962 | $268,492.46 | 313,662 | SEC Form 4 |
| Sullivan Timothy Eugene | APLS | Chief Financial Officer | Feb 12 '24 | Sell | $67.77 | 1,431 | $96,974.43 | 93,338 | SEC Form 4 |
| Watson David O. | APLS | General Counsel | Feb 12 '24 | Sell | $67.77 | 781 | $52,925.95 | 103,390 | SEC Form 4 |
| Townsend Adam J. | APLS | Chief Commercial Officer | Feb 12 '24 | Sell | $67.77 | 1,148 | $77,796.40 | 92,453 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Feb 12 '24 | Sell | $67.77 | 1,148 | $77,796.40 | 1,115,983 | SEC Form 4 |
| DeLong Mark Jeffrey | APLS | Chief Business & Strat Officer | Jan 29 '24 | Sell | $64.14 | 367 | $23,538.72 | 65,203 | SEC Form 4 |
| Townsend Adam J. | APLS | Chief Commercial Officer | Jan 29 '24 | Sell | $64.14 | 906 | $58,109.21 | 93,601 | SEC Form 4 |
| Lewis Karen | APLS | Chief People Officer | Jan 29 '24 | Sell | $64.14 | 367 | $23,538.72 | 47,270 | SEC Form 4 |
| Lewis Karen | APLS | Chief People Officer | Jan 29 '24 | Sell | $65.53 | 883 | $57,862.99 | 46,387 | SEC Form 4 |
| Francois Cedric | APLS | Chief Executive Officer | Jan 29 '24 | Sell | $64.14 | 2,843 | $182,344.90 | 317,624 | SEC Form 4 |
Latest Apellis Pharmaceuticals Inc. News
APLS Breaking Stock News: Dive into APLS Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Apellis Pharmaceuticals Enters Into Senior Secured Credit Facility With Sixth Street
GlobeNewswire
6 days ago
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
MT Newswires
11 days ago
Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing
Simply Wall St.
11 days ago
Analysts Are Updating Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates After Its First-Quarter Results
Insider Monkey
12 days ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
Simply Wall St.
12 days ago
Apellis Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GuruFocus.com
12 days ago
Apellis Pharmaceuticals Inc (APLS) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...
Zacks
13 days ago